NYSE:MRKMerck & Co., Inc. Stock Price, Forecast & News

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MRK shares have increased by 2.1% and is now trading at $80.91.
View which stocks have been most impacted by COVID-19.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Merck & Co., Inc..

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Merck & Co., Inc..

Merck & Co., Inc. (NYSE:MRK) posted its earnings results on Friday, July, 31st. The company reported $1.37 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.14 by $0.23. The company earned $10.87 billion during the quarter, compared to analyst estimates of $10.52 billion. Merck & Co., Inc. had a net margin of 22.20% and a return on equity of 52.94%. The firm's revenue was down 7.6% on a year-over-year basis. During the same quarter last year, the company earned $1.30 earnings per share.
View Merck & Co., Inc.'s earnings history.

Merck & Co., Inc. announced a quarterly dividend on Wednesday, July 29th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.61 per share on Wednesday, October 7th. This represents a $2.44 annualized dividend and a yield of 3.02%. The ex-dividend date of this dividend is Monday, September 14th.
View Merck & Co., Inc.'s dividend history.

Merck & Co., Inc. announced that its board has initiated a stock repurchase program on Thursday, October 25th 2018, which allows the company to buyback $10,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to purchase up to 5.1% of its shares through open market purchases. Shares buyback programs are usually a sign that the company's board believes its stock is undervalued.

Merck & Co., Inc. issued an update on its FY20 earnings guidance on Friday, July, 31st. The company provided earnings per share guidance of $5.63-5.78 for the period, compared to the Thomson Reuters consensus estimate of $5.31. The company issued revenue guidance of $47.2-48.7 billion, compared to the consensus revenue estimate of $47.33 billion.

14 equities research analysts have issued 1-year target prices for Merck & Co., Inc.'s shares. Their forecasts range from $89.00 to $105.00. On average, they anticipate Merck & Co., Inc.'s share price to reach $94.93 in the next twelve months. This suggests a possible upside of 17.3% from the stock's current price.
View analysts' price targets for Merck & Co., Inc..

News articles about MRK stock have trended extremely negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Merck & Co., Inc. earned a media sentiment score of -4.1 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days.
View the latest news about Merck & Co., Inc..

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), Walt Disney (DIS), JPMorgan Chase & Co. (JPM), Verizon Communications (VZ), AbbVie (ABBV) and Exxon Mobil (XOM).

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Merck & Co., Inc.'s stock is owned by a number of institutional and retail investors. Top institutional investors include Bank of New York Mellon Corp (1.25%), Sumitomo Mitsui Trust Holdings Inc. (0.50%), Macquarie Group Ltd. (0.46%), Swiss National Bank (0.43%), California Public Employees Retirement System (0.40%) and Fisher Asset Management LLC (0.36%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, Ashley Watson, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Leslie A Brun, Merck & Co, Inc, Richard R Deluca, Rita A Karachun, Robert M Davis, Roger M Perlmutter, Sanat Chattopadhyay, Thomas H Glocer and Wendell P Weeks.
View institutional ownership trends for Merck & Co., Inc..

MRK stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Toronto Dominion Bank, Bank of Nova Scotia, Thornburg Investment Management Inc., Victory Capital Management Inc., Bank of Montreal Can, Menora Mivtachim Holdings LTD., and Railway Pension Investments Ltd. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Frank Clyburn, Julie L Gerberding, and Wendell P Weeks.
View insider buying and selling activity for Merck & Co., Inc..

MRK stock was acquired by a variety of institutional investors in the last quarter, including Sarasin & Partners LLP, Ceredex Value Advisors LLC, Sumitomo Mitsui Trust Holdings Inc., Alecta Pensionsforsakring Omsesidigt, Candriam Luxembourg S.C.A., LSV Asset Management, Strs Ohio, and Rovida Advisors Inc..
View insider buying and selling activity for Merck & Co., Inc..

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MRK stock can currently be purchased for approximately $80.91.

Merck & Co., Inc. has a market capitalization of $204.64 billion and generates $46.84 billion in revenue each year. The company earns $9.84 billion in net income (profit) each year or $5.19 on an earnings per share basis. Merck & Co., Inc. employs 71,000 workers across the globe.

The official website for Merck & Co., Inc. is www.merck.com.

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]